Reversal of T-cell Tolerance in Myelodysplastic Syndrome through Lenalidomide Immune Modulation

Reversal of T-cell tolerance in myelodysplastic syndrome through lenalidomide immune modulation

• Publication year

  2011

• Venue

  Leukemia

• Publication date

  2011-11-22

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/leu.2011.359PMID 22193963PMCID 3321111
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis

  2011cited by this paper
• Lenalidomide Enhances Antigen-Specific Activity and Decreases CD45RA Expression of T Cells from Patients with Multiple Myeloma

  2011cited by this paper
• Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.

  2011cited by this paper
• Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

  2010cited by this paper
• A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide

  2009cited by this paper
• Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes.

  2009cited by this paper
• Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma.

  2009cited by this paper
• Proteomic and genetic approaches identify Syk as an AML target.

  2009cited by this paper
• Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs.

  2008cited by this paper
• T cell subset-specific susceptibility to aging.

  2008cited by this paper
• Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.

  2008cited by this paper
• Resistance to c-KIT kinase inhibitors conferred by V654A mutation

  2007cited by this paper
• A Family of Human MicroRNA Genes from Miniature Inverted-Repeat Transposable Elements

  2007cited by this paper
• New developments in FcεRI regulation, function and inhibition

  2007cited by this paper
• WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues

  2007cited by this paper
• The colorectal microRNAome.

  2006cited by this paper
• Integrated signalling pathways for mast-cell activation

  2006cited by this paper
• Efficacy of lenalidomide in myelodysplastic syndromes.

  2005cited by this paper
• Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis.

  2005cited by this paper
• Diagnostic criteria and classification of mastocytosis: a consensus proposal.

  2001cited by this paper
• Interleukin-7 mediates the homeostasis of naïve and memory CD8 T cells in vivo

  2000cited by this paper
• Thymic aging and T‐cell regeneration

  1997cited by this paper
• CD4 CD7 CD28 T Cells Are Expanded in Rheumatoid Arthritis and Are Characterized by Autoreactivity

  1996cited by this paper
• Expansion of cytotoxic CD8+ CD28− T cells in healthy ageing people, including centenarians

  1996cited by this paper
• CD4+ CD7- CD28- T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity.

  1996cited by this paper
• Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy.

  1995cited by this paper
• Antigen presentation by chemically modified splenocytes induces antigen- specific T cell unresponsiveness in vitro and in vivo

  1987cited by this paper
• Academic Editor: Frederick R.

  year unknowncited by this paper

• Small-Molecule Compounds Boost CAR-T Cell Therapy in Hematological Malignancies

  2023cites this paper
• Targeting cereblon in hematologic malignancies.

  2022cites this paper
• Enhanced Chimeric Antigen Receptor T Cell Therapy through Co-Application of Synergistic Combination Partners

  2022cites this paper
• Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS

  2020influential citation
• Retuning the immune system in myelodysplastic syndromes: from immunomodulatory approaches to vaccination strategies and non myeloablative hemopoietic cell transplant.

  2019cites this paper
• Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T cell Function against Multiple Myeloma Is Enhanced in the Presence of Lenalidomide

  2019cites this paper
• The Yin and Yang of myelodysplastic syndromes and autoimmunity: The paradox of autoimmune disorders responding to therapies specific for MDS.

  2019cites this paper
• Deep sequencing of bone marrow microenvironments of patients with del(5q) myelodysplastic syndrome reveals imprints of antigenic selection as well as generation of novel T-cell clusters as a response pattern to lenalidomide

  2019cites this paper
• Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon

  2018cites this paper
• Pilot trial of K562/GM-CSF whole-cell vaccination in MDS patients

  2018cites this paper
• Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling

  2018cites this paper
• Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia

  2017cites this paper
• Mechanistic and Clinical Aspects of Lenalidomide Treatment for Chronic Lymphocytic Leukemia.

  2016cites this paper
• The immune landscape of myelodysplastic syndromes.

  2016cites this paper
• New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide.

  2015cites this paper
• High level of full‐length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide

  2015cites this paper
• Is There a Role for Flow Cytometry in the Evaluation of Patients With Myelodysplastic Syndromes?

  2015cites this paper
• Treatment with lenalidomide induces immunoactivating and counter‐regulatory immunosuppressive changes in myeloma patients

  2014cites this paper
• Lenalidomide targets the T-cell co-stimulatory pathway to mediate immune modulation

  2012influential citation
• Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial

  2012cites this paper
• Molecular Action of Lenalidomide in Lymphocytes and Hematologic Malignancies

  2012cites this paper
• Naïve T-cells in Myelodysplastic Syndrome Display Intrinsic Human Telomerase Reverse Transcriptase (hTERT) Deficiency

  2012cites this paper
• Targeting Tumor-Related Immunosuppression using Metronomic Cyclophosphamide in Combination with Lenalidomide -New Mechanisms for Old Drugs

  2012cites this paper